Product Description
A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02324257)
Mechanisms of Action: CEA Binder, CD3 Binder
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, France, Israel, South Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03337698 |
Morpheus Lung | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2025-10-14 |
12% |
2025-12-13 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|